CSLLY:OTC-CSL Limited (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 106.41

Change

0.00 (0.00)%

Market Cap

USD 96.16B

Volume

0.06M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

N/A

USD167.99B 29.71 2.87
CMXHF CSL Limited

N/A

USD94.62B 45.29 26.33
GNMSF Genmab A/S

N/A

USD28.04B 121.29 3.24
UCBJF UCB SA

N/A

USD19.93B 19.80 17.47
UCBJY UCB SA

N/A

USD19.87B 19.75 17.47
SBMFF Sino Biopharmaceutical Limited

N/A

USD19.71B 31.21 2.97
SBHMY Sino Biopharmaceutical Limited

N/A

USD19.71B 28.00 2.97
PPTDF PeptiDream Inc

N/A

USD7.19B 260.99 1.65
IDRSF Idorsia Ltd

N/A

USD5.36B 130.60 N/A
ABCZF Abcam plc

N/A

USD5.21B 57.64 114.95

ETFs Containing CSLLY

Symbol Name Weight Mer Price(Change) Market Cap
EWA iShares MSCI Australia ET.. 0.00 % 0.50 %

N/A

USD1.77B
DXS6:F Xtrackers MSCI Pacific ex.. 0.00 % 0.45 %

N/A

USD0.63B
UIMD:XETRA UBS ETF - MSCI Pacific (e.. 0.00 % 0.30 %

N/A

USD0.14B
SXR1:XETRA iShares VII PLC - iShares.. 0.00 % 0.20 %

N/A

USD2.21B
PAC:XETRA BNP Paribas Easy MSCI Pac.. 0.00 % 0.00 %

N/A

N/A
IBC6:XETRA iShares MSCI Australia UC.. 0.00 % 0.50 %

N/A

USD0.65B
H4ZH:XETRA HSBC MSCI Pacific ex Japa.. 0.00 % 0.40 %

N/A

USD0.23B
EUNJ:XETRA iShares MSCI Pacific ex-J.. 0.00 % 0.60 %

N/A

USD0.27B
DXS6:XETRA Xtrackers MSCI Pacific ex.. 0.00 % 0.45 %

N/A

USD0.63B
DX2S:XETRA Xtrackers S&P ASX 200.. 0.00 % 0.50 %

N/A

USD0.10B
UIMD:F UBS ETF - MSCI Pacific (e.. 0.00 % 0.30 %

N/A

USD0.14B
SXR1:F iShares VII PLC - iShares.. 0.00 % 0.20 %

N/A

USD2.21B
PAC:F BNP Paribas Easy MSCI Pac.. 0.00 % 0.00 %

N/A

N/A
IBC6:F iShares MSCI Australia UC.. 0.00 % 0.50 %

N/A

USD0.65B
H4ZH:F HSBC MSCI Pacific ex Japa.. 0.00 % 0.40 %

N/A

USD0.23B
DX2S:F Xtrackers S&P ASX 200 UCI.. 0.00 % 0.50 %

N/A

USD0.09B
HAUD iShares Currency Hedged M.. 0.00 % 0.53 %

N/A

USD2.37M
MXJ:PA HSBC MSCI Pacific ex Japa.. 0.00 % 0.40 %

N/A

USD0.23B
EPEJ:PA BNP Paribas Easy MSCI Pac.. 0.00 % 0.00 %

N/A

N/A
CP9:PA Amundi Funds - Amundi Ind.. 0.00 % 0.00 %

N/A

N/A
XPXJ:LSE Xtrackers MSCI Pacific ex.. 0.00 % 0.45 %

N/A

USD0.51B
VDPX:LSE Vanguard FTSE Developed A.. 0.00 % 0.15 %

N/A

USD0.91B
SPXJ:LSE iShares MSCI Pacific ex-J.. 0.00 % 0.60 %

N/A

USD0.17B
SAUS:LSE iShares MSCI Australia UC.. 0.00 % 0.50 %

N/A

USD0.26B
IPXJ:LSE iShares MSCI Pacific ex-J.. 0.00 % 0.60 %

N/A

USD0.27B
IAUS:LSE iShares MSCI Australia UC.. 0.00 % 0.50 %

N/A

USD0.65B
HMXJ:LSE HSBC MSCI Pacific ex Japa.. 0.00 % 0.40 %

N/A

USD0.09B
CPXJ:LSE iShares VII PLC - iShares.. 0.00 % 0.20 %

N/A

USD2.21B
RFAP First Trust RiverFront Dy.. 0.00 % 0.83 %

N/A

USD8.63M
QEFA SPDR MSCI EAFE StrategicF.. 0.00 % 0.30 %

N/A

USD0.52B
1390:TSE UBS ETF - MSCI Pacific (e.. 0.00 % 0.30 %

N/A

USD0.14B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.40% 20% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.40% 20% F 23% F
Trailing 12 Months  
Capital Gain 0.87% 39% F 44% F
Dividend Return 0.51% 40% F 8% F
Total Return 1.38% 39% F 43% F
Trailing 5 Years  
Capital Gain 182.48% 78% C+ 75% C
Dividend Return 8.98% 60% D- 31% F
Total Return 191.46% 80% B- 75% C
Average Annual (5 Year Horizon)  
Capital Gain 27.92% 59% F 72% C-
Dividend Return 1.22% 67% D+ 33% F
Total Return 29.14% 59% F 71% C-
Risk Return Profile  
Volatility (Standard Deviation) 15.33% 99% A+ 83% B
Risk Adjusted Return 190.12% 100% A+ 100% A+
Market Capitalization 96.16B 100% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 46.11 29% F 15% F
Price/Book Ratio 13.44 33% F 12% F
Price / Cash Flow Ratio 38.64 6% F 5% F
EV/EBITDA 26.33 28% F 14% F
Management Effectiveness  
Return on Equity 35.70% 95% A 96% A
Return on Invested Capital 21.19% 67% D+ 83% B
Return on Assets 12.22% 97% A+ 96% A
Debt to Equity Ratio 88.60% 11% F 22% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.12 76% C 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.